BiotechTube

Oral Anticoagulant + Antiplatelet Drug

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke, Atrial Fibrillation, Atherothrombosis

Trial Timeline

Apr 6, 2017 → Jul 18, 2023

NCT ID
NCT03062319

About Oral Anticoagulant + Antiplatelet Drug

Oral Anticoagulant + Antiplatelet Drug is a approved stage product being developed by Pfizer for Ischemic Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT03062319. Target conditions include Ischemic Stroke, Atrial Fibrillation, Atherothrombosis.

What happened to similar drugs?

9 of 13 similar drugs in Ischemic Stroke were approved

Approved (9) Terminated (2) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅RepathaAmgenApproved
✅celecoxib + ibuprofen + placeboPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
✅Enoxaparin sodiumSanofiApproved
✅Huatuo Zaizao PillsGuangzhou Baiyunshan Pharmaceutical HoldingsApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03062319ApprovedTerminated

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
42
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
RepathaAmgenApproved
35